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Hemolysis, elevated liver enzymes and low platelets
(HELLP) syndrome, a severe variant of preeclamp-
sia/eclampsia, characterized by intravascular hemolysis,
elevated levels of liver enzymes and a low platelet count,
may cause many maternal antepartum or postpartum
problems. It is known that about 20% of women with
severe preeclampsia or eclampsia may progress to
HELLP syndrome, while mortality rates vary from 0% to
24% [1]. Herein, we present a case of a twin pregnancy
complicated by severe preeclampsia and HELLP syn-
drome with unusually high serum aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) levels
up to 3,894 U/L and 3,581 U/L, respectively. Neither
hepatic rupture nor failure was induced by HELLP syn-
drome in a self-limiting clinical course post partum.
A 46-year-old woman, gravida 1, para 0, conceived
twins subsequent to in vitro fertilization and embryo
transfer, although she developed preterm labor as early
as the 26th gestational week. Prior to her pregnancy,
this woman revealed an otherwise normal blood pres-
sure and liver enzymes. Tocolytic treatment with rito-
drine and magnesium sulfate for preterm labor, and
corticosteroids to facilitate fetal lung maturation were
used. Intermittent bouts of hypertension with systolic
blood pressure reaching levels as high as 150 mmHg
and diastolic blood pressure levels up to 90 mmHg com-
bined with a puffy face and general edema were noted
from the 28th gestational week onward. Risk factors for
preeclampsia, including advanced age, nulliparity and
twins, were relevant to this patient, with imminent pro-
gression to preeclampsia. Not until the 33rd gestational
week did the woman reveal significant proteinuria.
Simultaneously, this woman complained of orthopnea
and shortness of breath as the chest film showed 
pulmonary edema. This patient’s blood pressure re-
mained about 150/90 mmHg. Antepartum fetal sur-
veillance was reassuring from the non-stress test and
amniotic fluid index. Cesarean section was resisted until
maternal compromise (day 9 in hospital) evidenced 
by preeclampsia and HELLP syndrome (hemoglobin,
10.4 g/dL; platelets, 148,000 per μL; serum AST and
ALT levels, 101 and 139 U/L, respectively). Preterm twins
were born with normal Apgar scores of 8 and 9 at 1
and 5 minutes, respectively, post delivery, with one infant
weighing 2,058 g and the other 1,660 g. The patient re-
covered steadily after oxygen supplementation, diuret-
ics, and fluid restriction over 24 hours.
Two days (day 11 in hospital) after delivery, the pa-
tient developed right upper abdominal pain, soon fol-
lowed by development of a somewhat jaundiced face.
Serum biochemistry investigations revealed highly in-
creased AST and ALT levels of 3,894 and 3,581 U/L,
respectively, along with total and direct serum bilirubin
levels of 2.8 and 0.9 mg/dL, respectively, lactate dehy-
drogenase 3,627 U/L, and uric acid 8.3 mg/dL (day 11 in
hospital). No evidence of the existence of any hepatitis
virus was detected from the serum study, and the pa-
tient’s postoperative hemoglobin declined from 7.7 g/
dL to 6.8 g/dL in 24 hours (days 11 to 12 in hospital).
The coagulation profile included a mildly low platelet
count of 140,000 per μL and a fairly normal pro-
thrombin time and partial thromboplastin time, a fi-
brin degradation protein level of greater than 40 μg/mL
(normal, < 10 μg/mL), a D-dimer level of 5,522 ng/mL
(normal,<500ng/mL), and a fibrinogen level of 397mg/
dL (normal, 200–400 mg/dL) 2 days after delivery (day
11 in hospital). Abdominal ultrasound in this patient
revealed mild infiltration of fatty liver without evidence
of hepatic rupture or hemoperitoneum.
A total of 30 mg dexamethasone was administered
to this patient for her hepatic dysfunction, such therapy
consisting of three separate doses at 12-hour intervals.
Throughout the hospital course, the patient always
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remained alert. The unusually high serum AST and ALT
levels present at the 33rd gestational week declined
drastically to 229 and 1,184 U/L, respectively, 5 days
post partum (day 14 in hospital) and to 63 and
399 U/L, respectively, 9 days post partum (day 18 in
hospital; Figure). The clinical symptoms and laboratory
data revealed a dramatic improvement over the 2-week
postpartum period, while her serum AST and ALT levels
(23 and 28 U/L, respectively) indicated no liver disease.
Preeclampsia remains quite a common obstetric
complication, and plays a role in maternal death. HELLP
syndrome accounts for around 20% of women with
severe preeclampsia in the USA [1]. The pathophysiol-
ogy of preeclampsia may result from microangiopathy
that leads to injury of the vascular endothelium with
systemic involvement [1]. HELLP syndrome could be
considered to be a type of “gastrointestinal preeclamp-
sia” and a placenta-instigated, liver-targeted acute
inflammatory condition [2,3]. Maternal death caused
by HELLP syndrome featuring unusually high serum
levels of AST and ALT is still a matter of concern for cli-
nicians, because there appears to be a relative paucity
of optimal treatment modalities for the condition to
avoid possible fatal sequelae such as subcapsular hem-
orrhage, hepatic rupture, disseminated intravascular
coagulopathy, and sepsis [4]. Recent studies of mater-
nal morbidities associated with HELLP syndrome
include eclampsia (6%), placental abruption (10%),
acute renal failure (5%), pulmonary edema (10%), and
subscapular liver hematoma (1.6%) [5].
Among the toxicities of beta-mimetic agents such
as ritodrine, pulmonary edema is a well-known exam-
ple of their activation of the renin-angiotensin sys-
tem, and increased sodium and water resorption [6].
In addition, to be borne in mind is the possibility of a
synergistic effect with combined magnesium sulfate
treatment for poorly controlled preterm labor even at
a safe therapeutic dosage. Elevation of liver enzymes is
a rare complication of ritodrine which occurs more
frequently in a twin than a singleton pregnancy (9.1%
vs. 1.9%) [7]. It is difficult to exclude the possibility
that this patient had ritodrine-induced liver function
impairment alone, but preeclampsia complicated with
HELLP syndrome is likely to be the reason for such
high serum AST levels. Briefly, the changes in volume
homeostasis and damage to the vascular endothelium
could be the mitigating factors in all patients with
preeclampsia and those subsequently progressing to
HELLP syndrome.
Whether corticosteroid treatment actually improves
HELLP syndrome remains controversial in the litera-
ture [8,9]. Following positive outcomes, steroids may
play an effective role as regards reducing the mortality
and morbidity rate in women suffering from HELLP
syndrome [10]. However, sufficient evidence needs to
be gained from large-scale studies [11]. According to
our experience presented herein, corticosteroid ther-
apy did not seem to be harmful in HELLP syndrome
featuring unusually high serum AST and ALT levels.
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Figure. The change in liver enzyme levels and hospital course of
the patient with HELLP (hemolysis, elevated liver enzymes and
low platelets) syndrome. AST = aspartate aminotransferase;
ALT = alanine aminotransferase.
Taiwan J Obstet Gynecol • September 2009 • Vol 48 • No 3310
C.K. Lin, et al
8. Martin JN Jr, Thigpen BD, Rose CH, Cushman J, Moore A,
May WL. Maternal benefit of high-dose intravenous corti-
costeroid therapy for HELLP syndrome. Am J Obstet Gynecol
2003;189:830–4.
9. Fonseca JE, Mendez, Catano C, Arias F. Dexamethasone
treatment does not improve the outcome of women with
HELLP syndrome: A double-blind, placebo-controlled, ran-
domized clinical trial. Am J Obstet Gynecol 2005;193:1591–8.
10. Magann EF, Bass D, Chauhan SP, Sullivan DL, Martin RW,
Martin JN Jr. Antepartum corticosteroids: disease stabilization
in patients with the syndrome of hemolysis, elevated liver
enzymes, and low platelets (HELLP). Am J Obstet Gynecol
1994;171:1148–53.
11. Matchaba P, Moodley J. Corticosteroids for HELLP syn-
drome in pregnancy. Cochrane Database Syst Rev 2004;(1):
CD002076.
